| Symbol | WVE |
|---|---|
| Name | WAVE LIFE SCIENCES LTD. |
| Sector | HEALTH CARE |
| Region | Asia |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | MARINA ONE EAST TOWER,7 STRAITS VIEW NO. 12-00, SINGAPORE, 18936, Singapore |
| Telephone | +65 62363388 |
| Fax | — |
| — | |
| Website | https://www.wavelifesciences.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001631574 |
| Description | WAVE Life Sciences Ltd is a preclinical biopharmaceutical company based in Singapore. It owns a diverse pipeline of nucleic acid therapeutics meant to address rare genetic diseases related to the central nervous system, muscles, eyes, liver, and skin. Its nucleic acid therapeutics target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Additional info from NASDAQ: |
New Form EFFECT - Wave Life Sciences, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 9999999995-26-002660 <b>Size:</b> 2 KB
Read moreWagner Heidi L 🟡 adjusted position in 7.0K shares (1 derivative) of Wave Life Sciences, Inc. (WVE) at $6.01 Transaction Date: Aug 11, 2026 | Filing ID: 349963
Read moreRawcliffe Adrian 🔴 sold 12.7K shares of Wave Life Sciences, Inc. (WVE) at $5.29 Transaction Date: Aug 12, 2026 | Filing ID: 349962
Read moreTAKANASHI KEN 🔴 sold 3.9K shares of Wave Life Sciences, Inc. (WVE) at $6.01 Transaction Date: Aug 11, 2026 | Filing ID: 349961
Read moreTan Aik Na 🔴 sold 432 shares of Wave Life Sciences, Inc. (WVE) at $6.01 Transaction Date: Aug 11, 2026 | Filing ID: 349960
Read more📋 ADRIAN G RAWCLIFFE (Director) plans to sell 13K shares of WAVE LIFE SCIENCES INC (at $5.04 each, total $64K) Filed: Aug 12, 2026 | ID: 008025
Read more📋 HEIDI L WAGNER (Director) plans to sell 7K shares of WAVE LIFE SCIENCES, INC. (at $6.07 each, total $42K) Filed: Aug 11, 2026 | ID: 007963
Read moreNew Form SCHEDULE 13D/A - Wave Life Sciences, Inc. <b>Filed:</b> 2026-08-11 <b>AccNo:</b> 0001346824-26-000222 <b>Size:</b> 21 KB
Read moreNASDAQ traded attribute type Security_Name was changed. Previous value: Wave Life Sciences Ltd. - Ordinary Shares. New value: Wave Life Sciences, Inc. - Common Stock.
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07209332 | Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystr… | Phase2 | Duchenne Muscular Dystrophy | Enrolling_By_Invitation | 2025-12-28 | 2029-03-01 | ClinicalTrials.gov |
| NCT06842186 | A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity | Phase1 | Overweight and Obesity | Recruiting | 2025-01-31 | 2027-12-01 | ClinicalTrials.gov |
| NCT06405633 | A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses S… | Phase1 | Alpha-1 Antitrypsin Deficiency | Active_Not_Recruiting | 2024-07-19 | 2026-09-01 | ClinicalTrials.gov |
| NCT06186492 | A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics… | Phase1 | Alpha-1 Antitrypsin Deficiency (AATD) | Completed | 2023-11-14 | 2025-02-13 | ClinicalTrials.gov |
| NCT05683860 | Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated… | Phase1 | ALS | Terminated | 2022-12-14 | 2023-06-30 | ClinicalTrials.gov |
| NCT04906460 | Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORW… | Phase1 | Duchenne Muscular Dystrophy | Recruiting | 2021-09-28 | 2027-04-24 | ClinicalTrials.gov |
| NCT05032196 | Study of WVE-003 in Patients With Huntington's Disease | Phase1 | Huntington Disease | Completed | 2021-09-06 | 2024-05-24 | ClinicalTrials.gov |
| NCT04931862 | Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclero… | Phase1 | ALS | Terminated | 2021-06-28 | 2023-06-27 | ClinicalTrials.gov |
| NCT04617847 | Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-12010… | Phase1 | Huntington Disease | Terminated | 2020-04-13 | 2021-05-03 | ClinicalTrials.gov |
| NCT04617860 | Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-12010… | Phase1 | Huntington Disease | Terminated | 2019-09-24 | 2021-04-29 | ClinicalTrials.gov |
| NCT03907072 | Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension … | Phase2 | Duchenne Muscular Dystrophy | Terminated | 2019-09-04 | 2020-01-09 | ClinicalTrials.gov |
| NCT03508947 | Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystro… | Phase1 | Duchenne Muscular Dystrophy | Completed | 2018-01-24 | 2019-03-06 | ClinicalTrials.gov |
| NCT03225833 | Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease | Phase1 | Huntington's Disease | Terminated | 2017-07-17 | 2021-05-11 | ClinicalTrials.gov |
| NCT03225846 | Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease | Phase1 | Huntington's Disease | Terminated | 2017-07-17 | 2021-05-10 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| WVE-007 | Other | Phase PHASE1 | Overweight and Obesity | RECRUITING | NCT06842186 |
| Placebo | Other | Phase PHASE1 | Duchenne Muscular Dystrophy | COMPLETED | NCT03508947 |
| WVE-210201 | Other | Phase PHASE1 | Duchenne Muscular Dystrophy | COMPLETED | NCT03508947 |
| Placebo | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | TERMINATED | NCT03907072 |
| WVE-210201 (suvodirsen) | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | TERMINATED | NCT03907072 |
| WVE-120102 | Other | Phase PHASE1 | Huntington Disease | TERMINATED | NCT04617860 |
| WVE-120101 | Other | Phase PHASE1 | Huntington Disease | TERMINATED | NCT04617847 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | TERMINATED | NCT03225833 |
| WVE-120101 | Other | Phase PHASE1 | Huntington's Disease | TERMINATED | NCT03225833 |
| Placebo | Other | Phase PHASE1 | Huntington's Disease | TERMINATED | NCT03225846 |
| WVE-120102 | Other | Phase PHASE1 | Huntington's Disease | TERMINATED | NCT03225846 |
| WVE-004 | Other | Phase PHASE1 | ALS | TERMINATED | NCT05683860 |
| Placebo | Other | Phase PHASE1 | ALS | TERMINATED | NCT04931862 |
| WVE-004 | Other | Phase PHASE1 | ALS | TERMINATED | NCT04931862 |
| MD: Placebo | Other | Phase PHASE1 | Huntington Disease | COMPLETED | NCT05032196 |
| MD: 30mg WVE-003 | Other | Phase PHASE1 | Huntington Disease | COMPLETED | NCT05032196 |
| SAD: Pooled Placebo | Other | Phase PHASE1 | Huntington Disease | COMPLETED | NCT05032196 |
| SAD: 90mg WVE-003 | Other | Phase PHASE1 | Huntington Disease | COMPLETED | NCT05032196 |
| SAD: 60mg WVE-003 | Other | Phase PHASE1 | Huntington Disease | COMPLETED | NCT05032196 |
| SAD: 30mg WVE-003 | Other | Phase PHASE1 | Huntington Disease | COMPLETED | NCT05032196 |
| WVE-N531 | Other | Phase PHASE1 | Duchenne Muscular Dystrophy | RECRUITING | NCT04906460 |
| WVE-007 | Other | Phase PHASE1 | Obesity and Overweight | RECRUITING | NCT06842186 |
| WVE-N531 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT07209332 |
| WVE-006 | Other | Phase PHASE1 | Alpha-1 Antitrypsin Deficiency (AATD) | COMPLETED | NCT06186492 |
| WVE-006 | Other | Phase PHASE1 | Alpha-1 Antitrypsin Deficiency | ACTIVE_NOT_RECRUITING | NCT06405633 |
| WVE-007 | DRUG | Phase PHASE1 | Obesity and Overweight | RECRUITING | NCT06842186 |
| WVE-006 | DRUG | Phase PHASE1 | Alpha-1 Antitrypsin Deficiency | RECRUITING | NCT06405633 |
| MD: Placebo | DRUG | Phase PHASE1 | Huntington Disease | COMPLETED | NCT05032196 |
| MD: 30mg WVE-003 | DRUG | Phase PHASE1 | Huntington Disease | COMPLETED | NCT05032196 |
| SAD: Pooled Placebo | DRUG | Phase PHASE1 | Huntington Disease | COMPLETED | NCT05032196 |
| SAD: 90mg WVE-003 | DRUG | Phase PHASE1 | Huntington Disease | COMPLETED | NCT05032196 |
| SAD: 60mg WVE-003 | DRUG | Phase PHASE1 | Huntington Disease | COMPLETED | NCT05032196 |
| SAD: 30mg WVE-003 | DRUG | Phase PHASE1 | Huntington Disease | COMPLETED | NCT05032196 |
| WVE-004 | DRUG | Phase PHASE1 | ALS | TERMINATED | NCT05683860 |
| WVE-N531 | DRUG | Phase PHASE2 | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT07209332 |
| WVE-210201 (suvodirsen) | DRUG | Phase PHASE2 | Duchenne Muscular Dystrophy | TERMINATED | NCT03907072 |
| WVE-210201 | DRUG | Phase PHASE1 | Duchenne Muscular Dystrophy | COMPLETED | NCT03508947 |
| WVE-120102 | DRUG | Phase PHASE1 | Huntington Disease | TERMINATED | NCT04617860 |
| Placebo | DRUG | Phase PHASE1 | ALS | TERMINATED | NCT04931862 |
| WVE-120101 | DRUG | Phase PHASE1 | Huntington Disease | TERMINATED | NCT04617847 |